◀ Back to MAP2K1

MAP2K1 — PTK6

Text-mined interactions from Literome

Matsumoto et al., Br J Pharmacol 2006 (Diabetes Mellitus, Type 2...) : OLETF rats exhibited ( vs. age matched LETO rats ) : ( 1 ) greater potentiation of high-K ( + ) -induced contraction by 10 microM LPC - a potentiation attenuated by 10 microM genistein, protein tyrosine kinase ( PTK ) inhibitor, ( 2 ) greater potentiation of UK14,304 ( 10 approximately 100 nM ) -induced contractions by LPC ( 1 microM approximately 10 microM ) - a potentiation attenuated by 10 microM genistein, 50 microM tyrphostin A23 ( PTK inhibitor ) or 10 microM PD98059 ( MEK 1/2 inhibitor ), ( 3 ) greater basal and LPC ( 1 microM ) -induced ERK activities, ( 4 ) greater basal and 100 nM UK14,304 stimulated ERK2 activities in both the absence and presence of 10 microM LPC, ( 5 ) greater SOV ( 10 microM approximately 3 mM ) -induced contractions, ( 6 ) greater potentiation of SOV induced contractions by 10 microM LPC - a potentiation suppressed by 10 microM PD98059 or 10 microM genistein, ( 7 ) upregulation of GPR4 mRNA
Hisaoka et al., Brain Res 2008 (Glioma) : The amitriptyline induced phosphorylation of CREB was completely blocked by U0126 [ a mitogen activated protein ( MAP) kinase kinase 1 inhibitor ] and genistein ( a PTK inhibitor ), but not by inhibitors of protein kinase A, p38 MAP kinase, or Ca ( 2+ ) /calmodulin dependent kinase